Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Juvenile Myelomonocytic Leukemia
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Juvenile Myelomonocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence.[2] This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Primary care physicians.
Pediatric surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[3] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 3 · NCI website
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Juvenile Myelomonocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Treatment options for juvenile myelomonocytic leukemia (JMML) include the following:
Chemotherapy before hematopoietic stem cell transplant (HSCT).
Sources: Chemotherapy before hematopoietic stem cell transplant (HSCT)
HSCT.
Sources: HSCT
Source: Juvenile Myelomonocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Previous efforts to use chemotherapy before curative-intent HSCT have had a mixed and overall unsatisfactory impact on survival. However, control of symptoms has been aided by various lower- and higher-intensity regimens.[1,2]
Evidence (chemotherapy before HSCT):
In an attempt to cytoreduce leukemic burden, the combination of fludarabine and cytarabine with isotretinoin alone was given for two cycles before planned HSCT in 34 of 87 evaluable children with JMML in the Children's Oncology Group (COG) AAML0122 trial.[3]
In an attempt to cytoreduce leukemic burden, the combination of fludarabine and cytarabine with isotretinoin alone was given for two cycles before planned HSCT in 34 of 87 evaluable children with JMML in the Children's Oncology Group (COG) AAML0122 trial.[3]
In this group, the overall response rate (partial response [PR] and complete response [CR]) was 68%. However, achieving a CR before HSCT did not significantly improve overall survival, event-free survival (EFS), or relapse risk.
A phase II, single-arm, open-label trial included 18 children with newly diagnosed JMML who received single-agent azacitidine, given for 7 days in 28-day cycles.[4] Partially based on this trial, the U.S. Food and Drug Administration expanded the approved indications for azacitidine to include children with newly diagnosed JMML.
Sources: 4
A phase II, single-arm, open-label trial included 18 children with newly diagnosed JMML who received single-agent azacitidine, given for 7 days in 28-day cycles.[4] Partially based on this trial, the U.S. Food and Drug Administration expanded the approved indications for azacitidine to include children with newly diagnosed JMML.
The study found that 61% of patients had partial remissions after three cycles of treatment.
Responding patients, defined using the International JMML response criteria,[5] tended to be younger and had low-to-medium methylation classifications.
Sources: 5
Six patients became platelet-transfusion independent, and all responders had reductions in splenomegaly.
Seventeen of the 18 patients received an HSCT at a median of 5.5 months after diagnosis. Of these 17 patients, 14 remained leukemia-free at last follow-up (median, 23.8 months after HSCT).[4]
Sources: 4
Source: Juvenile Myelomonocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Evidence (HSCT):
A report from the European Working Group on Childhood Myelodysplastic Syndromes included 100 transplant recipients at multiple centers treated with a common preparative regimen of busulfan, cyclophosphamide, and melphalan, with or without antithymocyte globulin. Recipients had been treated with varying degrees of pretransplant chemotherapy or differentiating agents, and some patients had a splenectomy.[7]
Sources: 7
A report from the European Working Group on Childhood Myelodysplastic Syndromes included 100 transplant recipients at multiple centers treated with a common preparative regimen of busulfan, cyclophosphamide, and melphalan, with or without antithymocyte globulin. Recipients had been treated with varying degrees of pretransplant chemotherapy or differentiating agents, and some patients had a splenectomy.[7]
The 5-year EFS rate was 55% for children with JMML who underwent HSCT using HLA-identical matched family donor cells and 49% for children with JMML who underwent HSCT using unrelated donor cells.
The multivariate analysis showed no effect on survival of previous acute myeloid leukemia–like chemotherapy versus low-dose chemotherapy or no chemotherapy.
No effect on survival was observed for splenectomy pretransplant or difference in spleen size.
No difference in outcomes was found based on related versus unrelated donors.
Only age older than 4 years and female sex were shown to be poor prognostic factors for outcome and increased risk of relapse (relative risk [RR], 2.24 [1.07–4.69]; P = .032 for older age; RR, 2.22 [1.09–4.50]; P = .028 for females).[7]
Sources: 7
In one study, cord blood transplant produced the following results:[10][Level of evidence C2]
Sources: 10 · Level of evidence C2
In one study, cord blood transplant produced the following results:[10][Level of evidence C2]
The 5-year disease-free survival rate was 44%.
Outcomes were improved in children younger than 1.4 years at diagnosis, those with nonmonosomy 7 karyotype, and those receiving 5/6 to 6/6 HLA-matched cord units.
This suggests that cord blood can provide an additional donor pool for this group of children.
The use of reduced-intensity preparative regimens to decrease the adverse side effects of transplant have also been reported in small numbers of patients, generally for patients ineligible for myeloablative HSCT.[11,12]
The use of reduced-intensity preparative regimens to decrease the adverse side effects of transplant have also been reported in small numbers of patients, generally for patients ineligible for myeloablative HSCT.[11,12]
The COG conducted a randomized trial in children with JMML that compared a standard-intensity preparative regimen (busulfan/cyclophosphamide/melphalan) with a reduced-intensity regimen (busulfan/fludarabine).[13]
Sources: 13
The use of reduced-intensity preparative regimens to decrease the adverse side effects of transplant have also been reported in small numbers of patients, generally for patients ineligible for myeloablative HSCT.[11,12] › The COG conducted a randomized trial in children with JMML that compared a standard-intensity preparative regimen (busulfan/cyclophosphamide/melphalan) with a reduced-intensity regimen (busulfan/fludarabine).[13]
The trial closed to enrollment early when an interim analysis revealed a higher frequency of relapse/disease persistence (7 of 9 patients) in children who received the reduced-intensity regimen than in children who received the standard-intensity regimen (1 of 6 patients).
The role of conventional antileukemia therapy in the treatment of JMML is not defined. Determining the role of specific agents in the treatment of JMML is complicated because of the absence of consensus response criteria.[14] Some agents that have shown antileukemia activity against JMML include etoposide, cytarabine, thiopurines (thioguanine and mercaptopurine), isotretinoin, and farnesyl inhibitors, but none of these have been shown to improve outcome.[14-18]; [3][Level of evidence B4]
Sources: 14 · 14 · 18 · 3 · Level of evidence B4
Source: Juvenile Myelomonocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Disease recurrence is the primary cause of treatment failure for children with JMML after HSCT and occurs in 30% to 40% of cases.[6-8] While the role of donor lymphocyte infusions is uncertain,[19] reports indicate that approximately 50% of patients with relapsed JMML can be successfully treated with a second HSCT.[20]
In a prospective study, four children with relapsed JMML after stem cell transplant were treated with azacitidine. Three patients responded to azacitidine and were able to proceed to a second transplant.[21]
Sources: 21
In a prospective study, ten children with relapsed or refractory JMML were treated with oral trametinib (an MEK inhibitor) daily for up to 12 28-day cycles. Five patients had objective responses (three clinical PRs and two clinical CRs) within five cycles. Two patients had stable disease. All seven patients remained alive at a median follow-up of 24 months, including three who continued to receive trametinib off study (for 6, 24, and 24 months, respectively) without proceeding to HSCT. The four patients who underwent HSCT remained in CR at a median of 24 months of follow-up. The RAS pathway variants were no longer detected in the four patients who underwent HSCT, whereas the three other patients continued to have detectable variants without progressive disease while receiving trametinib. No severe adverse events were reported.[22]
Sources: 22
Source: Juvenile Myelomonocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 10, 2024. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
NCT05849662 (A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia [JMML]): This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with JMML.
Sources: NCT05849662
Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 5, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of newly diagnosed juvenile myelomonocytic leukemia (JMML) may include the following:
Sources: diagnosed · juvenile myelomonocytic leukemia
Combination chemotherapy followed by stem cell transplant.
Sources: Combination chemotherapy · stem cell transplant
Treatment of refractory or recurrent childhood JMML may include the following:
Sources: refractory · recurrent
A second stem cell transplant, for patients whose disease came back after the first stem cell transplant.
A clinical trial of targeted therapy with a tyrosine kinase inhibitor (trametinib).
Sources: clinical trial · targeted therapy · tyrosine kinase inhibitor · trametinib
Juvenile Myelomonocytic Leukemia
ClinicalTrials.gov recordMyelodysplastic Syndrome, Leukemia, Myelomonocytic, Juvenile
ClinicalTrials.gov recordLeukemia, Juvenile Myelomonocytic, JMML, JCML, Neurofibromatosis 1, CBL Syndrome
ClinicalTrials.gov recordJuvenile Myelomonocytic Leukemia
ClinicalTrials.gov recordLeukemia
ClinicalTrials.gov recordLeukemia
ClinicalTrials.gov recordJuvenile Myelomonocytic Leukemia
ClinicalTrials.gov recordAcute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
ClinicalTrials.gov recordJuvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1
ClinicalTrials.gov recordJuvenile Myelomonocytic Leukemia
Approaches to Recurrence After HSCT or Refractory JMML
VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of: • Adult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if...
DailyMed label